TTelum Therapeutics
Telum Therapeutics is a clinical-stage biotechnology company developing next-generation antimicrobial therapies based on engineered phage lytic proteins and antimicrobial peptides, using its proprietary APEXp platform that combines metagenomic datasets (including bacteriophages harvested from unexplored caves), synthetic biology and generative AI. Its lead program targets hospital-acquired and ventilator-associated bacterial pneumonia caused by multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Founded in Navarra in 2019, it is headquartered in Noáin (Pamplona metro area) with a US entity in New York, and closed an €18M Series A in mid-2026 led by the AMR Action Fund; Dr. Subhendu Basu became CEO in 2024, with founder Roberto Díez-Martínez moving to COO.
Founders
Global models 5
P
S
A
L
MIn the same niche 67 others
See all in the Start-ups Map →
Notes: Most funded first
Investors 8
Open as list →
Funding rounds 2
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-06-30 | Series A | €18M |
AMR Action Fund, Inveready
+4 more
|
| 2020-07-13 | Seed (estimated) | €4.1M |
Invivo Ventures
+2 more
|